Becton, Dickinson(BDX) - 2026 Q2 - Quarterly Results

Financial Performance - Revenues for the fiscal year 2026 reached $4,486 million, compared to $4,333 million in fiscal year 2025, reflecting a year-over-year increase of 3.5%[5] - Operating income for the fiscal year 2026 was $468 million, up from $282 million in fiscal year 2025, representing a significant increase of 66.1%[5] - Net income from continuing operations for the fiscal year 2026 was $311 million, compared to $147 million in fiscal year 2025, indicating a year-over-year growth of 111.6%[5] - Basic earnings per share for the fiscal year 2026 were $1.34, an increase from $1.05 in fiscal year 2025, marking a growth of 27.6%[5] - Revenues for the three months ended December 31, 2024, were reported at $4,333 million, with a gross margin of $1,797 million[7] - For the three months ended March 31, 2025, revenues increased to $4,480 million, with a gross margin of $1,861 million[8] - In the three months ended June 30, 2025, revenues further rose to $4,726 million, achieving a gross margin of $2,235 million[9] - Revenues for the three months ended September 30, 2025, were reported at $5,005 million, with an adjusted total also at $5,005 million[10] - For the twelve months ended September 30, 2025, revenues were $18,544 million, with adjusted revenues remaining the same[11] Operating Costs and Expenses - The company reported total operating costs and expenses of $4,018 million for the fiscal year 2026, compared to $4,051 million in fiscal year 2025, a decrease of 0.8%[5] - Research and development expenses for the fiscal year 2026 totaled $235 million, slightly down from $243 million in fiscal year 2025, showing a decrease of 3.3%[5] - Integration, restructuring, and transaction expenses amounted to $108 million in the fiscal year 2026, compared to $89 million in fiscal year 2025, reflecting an increase of 21.3%[5] - Research and development expenses were $243 million for the three months ended December 31, 2024, $232 million for March 31, 2025, and $230 million for June 30, 2025[7][8][9] - Selling and administrative expenses were $1,155 million for the three months ended December 31, 2024, $1,117 million for March 31, 2025, and $1,163 million for June 30, 2025[7][8][9] Adjusted Financial Metrics - The company reported a significant increase in gross margin percentage from 41.5% in Q4 2024 to 47.2% in Q2 2025[7][9] - Operating income for the three months was $536 million, adjusted to $1,292 million after accounting for various costs[10] - Net income from continuing operations for the quarter was $346 million, with an adjusted net income of $937 million[10] - Diluted earnings per share from continuing operations for the quarter were reported at $1.20, adjusted to $3.26[10] - Gross margin for the twelve months was $8,258 million, adjusted to $10,241 million[11] - Operating income for the twelve months was $1,941 million, adjusted to $4,666 million[11] - Net income from continuing operations for the year was $1,100 million, with an adjusted net income of $3,433 million[11] - Diluted earnings per share from continuing operations for the year were reported at $3.81, adjusted to $11.90[11] Regulatory and Compliance Costs - The company incurred costs related to European regulatory initiatives, which are considered one-off costs, impacting the comparability of earnings[1] - BD incurred charges of $297 million in fiscal year 2025 related to product liability and legal matters, impacting other operating expenses[13] - The company recognized $98 million and $38 million in product remediation costs in fiscal years 2025 and 2024, respectively, recorded in cost of products sold[13] - Costs incurred for compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation are recorded in cost of products sold and research and development expenses[13] - The company reported $67 million in accruals in fiscal year 2024 related to Italian government medical device payback legislation, impacting revenues[13] Management Insights - Management emphasizes the importance of non-GAAP measures for understanding operational performance and trends, while cautioning that these measures may differ from those used by other companies[2] - The company has indicated ongoing investments in product development and market expansion strategies to drive future growth[7][8][9] Other Operating Costs - BD's costs associated with integration and restructuring activities are recorded under integration, restructuring, and transaction expenses[13] - BD's amortization expense, primarily recorded in cost of products sold, is related to purchase accounting for acquisitions[13] - The company incurred costs for the separation of its former Diabetes Care business, recorded under other operating expenses[13] - Charges related to pension settlement costs amounted to $38 million in fiscal year 2025, recorded in other expenses[13] - Transaction costs and financing impacts from the Advanced Patient Monitoring acquisition are recorded under integration, restructuring, and transaction expenses, as well as interest expense[13] - BD's adjustments to reported results reflect costs that are considered outside of underlying operational results, affecting period-to-period comparability[13]